Bessemer Group’s Fulcrum Therapeutics FULC Stock Holding History

Bessemer Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.2M	Hold	286,988	–	–	﹤0.01%	801
2025 Q4	$3.25M	Hold	286,988	–	–	0.01%	612
2025 Q3	$2.64M	Hold	286,988	–	–	﹤0.01%	452
2025 Q2	$1.98M	Hold	286,988	–	–	﹤0.01%	479
2025 Q1	$827K	Hold	286,988	–	–	﹤0.01%	763
2024 Q4	$1.35M	Hold	286,988	–	–	﹤0.01%	711
2024 Q3	$1.02M	Hold	286,988	–	–	﹤0.01%	771
2024 Q2	$1.78M	Hold	286,988	–	–	﹤0.01%	531
2024 Q1	$2.71M	Hold	286,988	–	–	﹤0.01%	474
2023 Q4	$1.94M	Hold	286,988	–	–	﹤0.01%	486
2023 Q3	$1.27M	Hold	286,988	–	–	﹤0.01%	567
2023 Q2	$947K	Hold	286,988	–	–	﹤0.01%	658
2023 Q1	$818K	Hold	286,988	–	–	﹤0.01%	624
2022 Q4	$2.09M	Buy	286,988 +1,274	+0.4%	+$8.31K	0.01%	441
2022 Q3	$2.31M	Hold	285,714	–	–	0.01%	419
2022 Q2	$1.4M	Hold	285,714	–	–	﹤0.01%	512
2022 Q1	$6.76M	Sell	285,714 -23,707	-8%	-$336K	0.01%	238
2021 Q4	$5.47M	Sell	309,421 -1,197	-0.4%	-$23.7K	0.01%	240
2021 Q3	$8.76M	Buy	310,618 +24,904	+9%	+$472K	0.02%	224
2021 Q2	$2.99M	Hold	285,714	–	–	0.01%	283
2021 Q1	$3.37M	Hold	285,714	–	–	0.01%	277
2020 Q4	$3.35M	Hold	285,714	–	–	0.01%	265
2020 Q3	$2.27M	Hold	285,714	–	–	0.01%	314
2020 Q2	$5.23M	Hold	285,714	–	–	0.02%	286
2020 Q1	$3.41M	Hold	285,714	–	–	0.01%	334
2019 Q4	$4.75M	Hold	285,714	–	–	0.02%	348
2019 Q3	$1.9M	Buy	+285,714	New	+$3.16M	0.01%	531

Other funds holding FULC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

FTM

First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Bessemer Group's FULC Position: Q1 2026 in Review

Bessemer Group held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 286,988 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #801.

Bessemer Group first reported a position in FULC in Q3 2019 and has held it in 27 quarters since. The position peaked at $8.76M in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

Bessemer Group held 286,988 shares of Fulcrum Therapeutics worth $2.2M as of Q1 2026.
Bessemer Group left its Fulcrum Therapeutics share count unchanged in Q1 2026.
Fulcrum Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #801 holding.
Bessemer Group first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 27 quarters since.
Bessemer Group's Fulcrum Therapeutics position peaked at $8.76M in Q3 2021.
169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.